Tirapazamine
- Generic Name
- Tirapazamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H6N4O2
- CAS Number
- 27314-97-2
- Unique Ingredient Identifier
- 1UD32YR59G
- Background
Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia. Hence, tirapazamine is solely activated in those hypoxic areas of solid tumors. It is important to take into conside...
- Indication
For the treatment of head and neck cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-02-04
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00020696
- Locations
- πΊπΈ
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
πΊπΈArthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
πΊπΈUniversity of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00066742
- Locations
- πΊπΈ
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00006484
- Locations
- πΊπΈ
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
πΊπΈCCOP - Central Illinois, Decatur, Illinois, United States
πΊπΈCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
- Conditions
- First Posted Date
- 2003-05-16
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT00005078
- Locations
- πΊπΈ
City of Hope Medical Group, Pasadena, California, United States
πΊπΈUSC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
πΊπΈCity of Hope Medical Center, Duarte, California, United States
Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- California Cancer Consortium
- Target Recruit Count
- 30
- Registration Number
- NCT00033410
- Locations
- πΊπΈ
City of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈUniversity of California Davis Cancer Center, Sacramento, California, United States
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 150
- Registration Number
- NCT00025363
- Locations
- πΊπΈ
Children's Oncology Group, Arcadia, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.